---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-034460"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2022-12-05T23:59:59+00:00"
generated_at: "2026-06-21T09:37:19.702832+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Oncocyte CEO Ronald Andrews steps down; Joshua Riggs named Interim CEO, Louis Silverman appointed to board

## Summary
- Ronald Andrews resigns as President, CEO, and director, effective Dec 1, 2022.
- Joshua Riggs, previously General Manager Transplant, appointed Interim CEO effective Dec 2, 2022.
- Andrews receives severance: $500K cash, 12 months COBRA ($40,128), accelerated vesting of equity.
- Andrews to provide consulting services through Feb 28, 2023; receives stock options for 50,000 shares.
- Board appoints Louis Silverman as director; he is CEO of Hicuity Health, former CEO of Quality Systems.

## SEC filing metadata
- accession: 0001493152-22-034460
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2022-12-05T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315222034460/0001493152-22-034460-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315222034460/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-034460
- JSON: https://secwatch.observer/filing/0001493152-22-034460.json
- Plain text: https://secwatch.observer/filing/0001493152-22-034460.txt

## Key facts
- Executive change
  Ronald Andrews departed as President and Chief Executive Officer at Insight Molecular Diagnostics Inc..
  - Action: step down
  - Role: President and Chief Executive Officer
  source text: On November 30, 2022, Oncocyte Corporation (the “Company”) issued a press release announcing that Ronald Andrews will step down from his role as President and Chief Executive Officer and director of the Board of Directors of the Company (the “Board”), effective as of December 1, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000149315222034460/0001493152-22-034460-index.htm
- Executive change
  Joshua Riggs was appointed as Interim Chief Executive Officer at Insight Molecular Diagnostics Inc..
  - Action: appointed
  - Role: Interim Chief Executive Officer
  source text: and the appointment of Joshua Riggs as Interim Chief Executive Officer of the Company, effective as of December 2, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000149315222034460/0001493152-22-034460-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.